$SPKAU News
Last published 4y ago
- 4y agoSPKSPKAUVarian Biopharmaceuticals, Inc. and SPK Acquisition Corp. Announce Release of Investor Presentation Regarding Previously Announced Merger; Provide Corporate UpdateGlobeNewswireNAPLES, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a special p
- 4y agoSPKSPKAUVarian Biopharmaceuticals, Inc., a Precision Oncology Company, to Become Publicly Traded Through a Merger with SPK Acquisition Corp.GlobeNewswireVarian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor types Combined company expected to have a post-transaction pro forma equity value of approximately $116 mi
- 5y agoSPKAUSPK Acquisition Corp. Announces that Common Stock and Rights to Commence Separate Trading on or about July 23, 2021GlobeNewswireNEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- SPK Acquisition Corp. ("the Company" or "SPK") (NASDAQ:SPKAU), a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, reorganization or simi
- 5y agoSPKAUSPK Acquisition Corp. Announces Pricing of $50 Million Initial Public OfferingGlobeNewswireNEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- SPK Acquisition Corp. (NASDAQ:SPKAU, the ", Company", ))) announced today that it priced its initial public offering of 5,000,000 units at $10.00 per unit. The units will be listed on The NASDAQ Capital Marke